IP Verse

Anti-Pvrig Antibodies And Methods Of Use - EP3258951

The patent EP3258951 was granted to Compugen on Jan 29, 2020. The application was originally filed on Feb 19, 2016 under application number EP16707603A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3258951

COMPUGEN
Application Number
EP16707603A
Filing Date
Feb 19, 2016
Status
Granted And Under Opposition
Dec 27, 2019
Grant Date
Jan 29, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

WITEKOct 29, 2020WITEKADMISSIBLE
SURFACE ONCOLOGYOct 28, 2020BHOGALADMISSIBLE

Patent Citations (42) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0154316
DESCRIPTIONEP0401384
DESCRIPTIONEP1176195
DESCRIPTIONUS2004110704
DESCRIPTIONUS3773919
DESCRIPTIONUS4485045
DESCRIPTIONUS4544545
DESCRIPTIONUS5013556
DESCRIPTIONUS5057313
DESCRIPTIONUS5624821
DESCRIPTIONUS5648260
DESCRIPTIONUS5677425
DESCRIPTIONUS5811097
DESCRIPTIONUS5837243
DESCRIPTIONUS5869046
DESCRIPTIONUS5922845
DESCRIPTIONUS6121022
DESCRIPTIONUS6165745
DESCRIPTIONUS6194551
DESCRIPTIONUS6277375
DESCRIPTIONUS6331175
DESCRIPTIONUS7371826
DESCRIPTIONUS8883973
DESCRIPTIONWO0029004
DESCRIPTIONWO0042072
DESCRIPTIONWO03035835
DESCRIPTIONWO2004091658
DESCRIPTIONWO2009126688
DESCRIPTIONWO9429351
DESCRIPTIONWO9738731
DESCRIPTIONWO9954342
INTERNATIONAL-SEARCH-REPORTEP2067791
INTERNATIONAL-SEARCH-REPORTWO2004058805
INTERNATIONAL-SEARCH-REPORTWO2012178128
OPPOSITIONEP2067791
OPPOSITIONUS2014056890
OPPOSITIONWO2004058805
OPPOSITIONWO2012178128
OPPOSITIONWO2013184912
OPPOSITIONWO2016134333
OPPOSITIONWO2017041004
OTHEREP3258951

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Benjamin Murter, Xiaoyu Pan, Eran Ophir, Zoya Alteber, Meir Azulay, Rupashree Sen, Ofer Levy, Liat Dassa, Ilan Vaknin, Tal Fridman-Kfir, Ran Salomon, Achinoam Ravet, Ada Tam, Doron Levin, Yakir Vaknin, Evgeny Tatirovsky, Arthur Machlenkin, Drew Pardoll and Sudipto Ganguly, "Mouse PVRIG Has CD 8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity", Cancer Immunol. Res., (20190118), vol. 7, no. 2, page 244, XP055748070-
OPPOSITION- Gene Id., "PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34kDa KDa PVRIG antibody -middle region -Additional Information", Physiol. Genomics, (20060101), pages 201 - 218, XP055273924-
OPPOSITION- QUINONES et al., "High-throughput cellular assays using a well-less plate format", Poster abstract no. 2205 (New Technologies and Frontiers), 2011 American Society for Cell Biology (ASCB) Annual Meeting, Denver , CO, (20111203), pages 1 - 3, XP055748047-
OPPOSITION- ZHU YUWEN et al., "Identification of CD112R as a novel checkpoint for human T cells", Journal of Experimental Medicine, (20160208), vol. 213, no. 2, pages 167 - 176, XP002763687-
OPPOSITION- JOHNSTON et al., "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD 8+ T Cell Effector Function", Cancer Cell, (20141208), vol. 26, no. 6, doi:10.1016/j.ccell.2014.10.018, page 923, XP029111576
OPPOSITION- PAUKEN et al., "TIGIT and CD 226: Tipping the Balance Between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit", Cancer Cell, (20141208), vol. 26, doi:10.1016/j.ccell.2014.11.016, page 785, XP029111585
OPPOSITION- Christopher J Chan; Daniel M Andrews; Mark J Smyth, "Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer", Current Opinion in Immunology, (20120128), vol. 24, pages 246 - 251, XP055147483
OPPOSITION- Xu Zhuwei, Et Alboquan Jin, "A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions", Cellular & Molecular Immunology, (20100118), vol. 7, pages 11 - 19, XP055748061
OPPOSITION- Yoon Suk Ran , Tae-Don Kim, And Inpyo Choi, "Understanding of molecular mechanisms in natural killer cell therapy", Experimental & Molecular Medicine, (20150213), vol. 47, no. 2, page e141, XP055748040
OPPOSITION- Xin Yu; Kristin Harden; Lino C Gonzalez; Michelle Francesco; Eugene Chiang; Bryan Irving; Irene Tom; Sinisa Ivelja; Canio J Refino; Hilary Clark; Dan Eaton; Jane L Grogan, "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells", Nature Immunology., (20090101), vol. 10, no. 1, pages 48 - 57, XP055273979
OPPOSITION- STANIETSKY et al., "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity", PNAS, (20091020), vol. 106, no. 42, doi:10.1073/pnas.0903474106, page 17858, XP055215810
OPPOSITION- STANIETSKY, N. et al., "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity", Proceedings of the National Academy of Sciences (PNAS, (20091020), vol. 106, no. 42, pages 17858 - 17863, XP055215810
OPPOSITION- BACHELET et al., "Mast Cell Costimulation by CD 226/ CD 112 (DNAM- 1/Nectin-2): a novel interface in the allergic process", J. Biol. Chem., (20060915), vol. 281, doi:10.1074/jbc.M602359200, page 27190, XP055223948
OPPOSITION- BOTTINO et al., "Identification of PVR ( CD 165) and Nectin-2 ( CD 112) as Cell Surface Ligands for the Human DNAM-1 ( CD 226) Activating Molecule", J. Exp. Med., (20030811), vol. 198, no. 4, doi:10.1084/jem.20030788, page 557, XP055011690
OPPOSITION- ZHU et al., "Identification of CD 112R as a novel checkpoint for human T cells", J. Exp. Med., (20160111), vol. 213, no. 2, doi:10.1084/jem.20150785, pages 167 - 176, XP055314642
OPPOSITION- ARDOLINO et al., "DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA- damage response: relevance for NK-T cell interaction", Blood, (20110505), vol. 11718, page 4778, XP055748054
OPPOSITION- Rimas J Orentas; Jessica Nordlund; Jianbin He; Sivasish Sindiri; Crystal Mackall; Terry J Fry; Javed Khan, "Bioinformatic Description of Immunotherapy Targets for Pediatric T- Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison", Frontiers Oncol, (20140610), vol. 4, no. 134, pages 1 - 11, XP055397613
OPPOSITION- Joller N; Hafler J P; Brynedal B; Kassam N; Spoerl S; Levin S D; Sharpe A H; Kuchroo V K, "Cutting Edge: TIGIT Has T Cell -Intrinsic Inhibitory Functions", J. Immunol., (20110103), vol. 186, no. 3, pages 1338 - 1342, XP055319470
OPPOSITION- Lozano E; Dominguez-Villar M; Kuchroo V; Hafler D A, "The TIGIT/ CD 226 axis regulates human T cell function", J. Immunol., (20120316), vol. 188, page 3869, XP055557788
OPPOSITION- FUCHS et al., "Cutting edge: CD 96 (tactile) promotes NK cell -target cell adhesion by interacting with the poliovirus receptor ( CD 165", J. Immunol., (20040401), vol. 172, doi:10.4049/jimmunol.172.7.3994, page 3994, XP055344481

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents